SCHEMBL6504655

SCHEMBL6504655

CCc1ccc2[nH]c(C(CCC(C)C)n3c(=O)n(C(C)C)c4ccccc43)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.39
KLK7 P49862 1/20 0.35
POLB P06746 2/20 0.34
TAAR1 Q96RJ0 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
FPR2 P25090 1/20 0.33
ELANE P08246 1/20 0.32
SLC6A4 P31645 2/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
ATP4A P20648 1/20 0.31
ATP4B P51164 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB1 P18505 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRB2 P47870 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6241609 0.91 SLC6A2 (0.39) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6244320 0.91 SLC6A2 (0.39) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6243782 0.91 SLC6A2 (0.39) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6491765 0.90 SLC6A2 (0.45) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6502626 0.89 SLC6A2 (0.38) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6246043 0.87 SLC6A2 (0.40) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6494315 0.87 SLC6A2 (0.40) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6247507 0.85 PARP1 (0.42) SLC6A2KLK7TSHR
SCHEMBL6243560 0.85 AAK1 (0.40) SLC6A2KLK7POLBTAAR1KDM4E
SCHEMBL6247442 0.83 SCN10A (0.41) SLC6A2KLK7POLBTAAR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919331-B2 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-19 US disclosed
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents MAVS, ZC3HAV1, EIF2AK2 SLC6A2 4457/4885KLK7 4140/4885POLB 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.